Wednesday, July 8, 2026

biotech · Alzheimer Disease · Major Depressive Disorder · CGTX

Cognition Therapeutics

Cognition Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

2500 Westchester Ave, Purchase, New York 10577, US HQ
2007 Founded
32 Employees
Public company Type
CGTX · NYSE Ticker
Company details
Status
Public
HQ
2500 Westchester Ave, Purchase, New York 10577, US
Founded
2007
Employees
32
Programs
33
Drugs
26
Patents
12
Intelligence · Clinical Programs

Cognition Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Cognition Therapeutics.

Cognition Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 300 mg [C14] CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial
  2. CT1812

    COGNITION THERAPEUTICS INC

    Cognitive Impairment

    phase 1 small molecule completed

    1 trial
  3. CT1812

    COGNITION THERAPEUTICS INC

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  4. Itraconazole

    COGNITION THERAPEUTICS INC

    Drug Interaction

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Cognition Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.